Ex-10.16.3



 





EXHIBIT 10.16.3




SECOND AMENDMENT TO

SECOND AMENDED AND RESTATED LOAN AGREEMENT




     THIS SECOND AMENDMENT TO SECOND AMENDED AND RESTATED LOAN AGREEMENT (this
“Amendment”), dated July 18, 2007, is made and entered into on the terms and conditions
hereinafter set forth, by and between CUMBERLAND PHARMACEUTICALS, INC., a Tennessee corporation
(the “Borrower”), and BANK OF AMERICA, N.A., a national banking association (the
“Bank”).



RECITALS:




     1. The Borrower and the Bank are parties to a Second Amended and Restated Loan Agreement dated
as of April 6, 2006, as amended by that certain First Amendment to Second Amended and Restated Loan
Agreement dated as of December 31, 2006, (as the same heretofore has been or hereafter may be
further amended, restated, supplemented, extended, renewed, replaced or otherwise modified from
time to time, the “Loan Agreement”), pursuant to which the Bank has agreed to extend credit
to the Borrower subject to and upon the terms and conditions set forth in the Loan Agreement.



     2. The parties hereto desire to amend the Loan Agreement in certain respects as more
particularly hereinafter set forth.



     3. Capitalized terms used but not otherwise defined in this Amendment shall have the same
meanings as in the Loan Agreement.



AGREEMENTS:




     NOW, THEREFORE, in consideration of the mutual covenants and agreements hereinafter set forth,
and for other good and valuable consideration, the receipt and sufficiency of all of which are
hereby acknowledged, the parties hereto agree as follows:



     1. Amendment of Section 8.3. Section 8.3 (Funded Debt to EBITDA Ratio) of the Loan
Agreement is hereby amended by deleting the definition of “Funded Debt” and substituting the
following in lieu thereof:



“Funded Debt” means all outstanding liabilities for borrowed money and other
interest-bearing liabilities, including current and long term debt, capital lease
obligations, promissory notes, seller notes, letters of credit, if any, and any
obligations guaranteed by the Borrower, less the non-current portion of Subordinated
Liabilities.



     2. Amendment of Section 8.4. Section 8.4 (Minimum Fixed Charge Coverage Ratio) of the
Loan Agreement is hereby amended by deleting the entire section substituting the following in
lieu thereof:



To maintain on a consolidated basis a Minimum Fixed Charge Coverage Ratio of at
least 1.25:1.0 from and after the first quarter following the completion of the
Successful IPO.



“Minimum Fixed Charge Coverage Ratio” means the ratio of (a) EBITDAR minus
maintenance capital expenditures $50,000 per annum, minus cash income taxes, minus
dividends, withdrawals and other distributions, to (b) the sum of interest expense,
lease expense, rent expense and scheduled principal payments on term debt and the
current portion of capitalized lease obligations.



“EBITDAR” means the sum of EBITDA plus lease expense and rent expense.



 









 








“Successful IPO” shall mean the consummation by the Borrower of an initial
public offering of its common stock on terms and conditions reasonably acceptable to
the Bank, if as a result thereof the Borrower shall have cash on hand free and clear
of any liens and restrictions other than liens permitted by this agreement (net of
cash underwriting fees and cash payments to holders of the Borrower’s
Outstanding Preferred Shares and Options in connection with the
conversion of these shares to common stock), in a minimum amount of $50,000,000.



     3. Amendment of Section 8.7. Section 8.7 (Capital Expenditures) of the Loan Agreement
is hereby amended by deleting the first sentence and substituting the following in lieu thereof:



Not to make or incur capital expenditures (excluding capital lease obligations) in
an aggregate amount in excess of $1,000,000 during any fiscal year.



     4. Amendment of Section 8.8. Section 8.8 (Lease Expenditures) of the Loan Agreement
is hereby amended by deleting the entire section and substituting the following in lieu thereof:



Not to incur obligations for the operating leases of real or personal property
requiring payments in an aggregate amount in excess of $1,000,000 during any fiscal
year.



     5. Amendment of Section 8.16. Section 8.16 (Change of Management) of the Loan
Agreement is hereby amended by deleting the entire section and substituting the following in lieu
thereof:



Intentionally Omitted.



     6. Amendment of Section 8.17. Section 8.17 (Change of Ownership or Control) of the
Loan Agreement is hereby amended by deleting the entire section and substituting the following in
lieu thereof:



Intentionally Omitted.



     7. Amendment of Section 8.18. Section 8.18 (Additional Negative Covenants) of the
Loan Agreement is hereby amended by deleting clause (b), and substituting the following in lieu
thereof:



(b) Acquire or purchase a business or its assets, other than acquisitions in which,



(i) (A) (I) the business or assets relate to a product that has received all
necessary approvals from the Food and Drug Administration as well as any
other governmental agency regulating such product, (II) is currently
available for purchase in the appropriate consumer market, (III) such
acquisition shall not be financed, directly or indirectly with the proceeds
of any debt for money borrowed, including, without limitation, the Facility
No. 1 Commitment and (IV) after giving effect to such acquisition, the
Borrower is in compliance with the financial covenants set forth in
Sections 8.3 through 8.8 or (B) (I) the business or assets
relate to a product that has not yet received all necessary approvals from
the Food and Drug Administration or any other governmental agency regulating
such product, but is in the final stages of development, as determined by
Lender in its reasonable discretion, (II) following such acquisition,
the Borrower shall have cash on hand free and clear of any liens and
restrictions, other than liens permitted by this Agreement, in a minimum
amount of $10,000,000, (III) such acquisition shall not be financed,
directly or indirectly, with the proceeds of any debt for money borrowed,
including, without limitation, the Facility No. 1


-2-









 








Commitment and (IV) after giving effect to such acquisition, the Borrower is
in compliance with the financial covenants set forth in Sections 8.3
through 8.8;



(ii) the Borrower is the surviving entity in such acquisition;



(iii) any entities acquired in connection with such acquisition shall
promptly execute and deliver to the Bank such supplements or amendments to
the Loan Documents as the Bank deems necessary or advisable, which documents
and any required opinions shall be in form and substance, satisfactory to
the Bank; and



(iv) no event of default has occurred or is continuing at the time of, or
immediately following (and taking into account) such acquisition.



     8. Amendment of Section 10.1. Section 10.1 (Failure to Pay) of the Loan Agreement is
hereby amended by the entire section, and substituting the following in lieu thereof:



The Borrower fails to make a payment under this Agreement when due, provided,
however, that such failure shall not constitute an event of default hereunder, if no
other default or event of default has occurred and is continuing and such payment
is received by the Bank within three (3) days of the date such payment was due.



     9. Amendment of Section 10.3. Section 10.3 (Cross-Default) of the Loan Agreement is
hereby amended by deleting the entire section, and substituting the following in lieu thereof:



Any default occurs under any agreement in connection with any credit (the aggregate
outstanding amount of such credit is in excess of $250,000) (i) the Borrower (or any
Obligor) or any of the Borrower’s related entities or affiliates has obtained from
anyone else or (ii) that the Borrower (or any Obligor) or any of the Borrower’s
related entities or affiliates has guaranteed, provided, however, in the event that
such default occurs in connection with payment of sums due under the distribution
agreement relating to the Borrower’s purchase of exclusive rights to distribute
Kristalose® in North America, such default shall not be a cross-default so long as
(i) such payment is being contested in good faith and by appropriate proceedings,
for which adequate reserves in accordance with GAAP have been established on the
books of such Borrower and (ii) such refusal to pay could not reasonably be expected
to result in the termination of or the loss of any material rights under the
distribution agreement.



     10. Amendment of Section 10. Section 10 (Default and Remedies) of the Loan Agreement
is hereby amended inserting the following Section 10.15 (Change in Control) immediately following
Section 10.14:



10.15. Change in Control. If any individual, entity or group (as defined
in Section 13(d) of the Securities Exchange Act of 1934) shall obtain ownership or
control in one or a series of transactions of more than thirty (30%) of the common
stock or thirty (30%) of the voting power of the Borrower entitled to vote in the
election of members of the board of directors of the Borrower.



     11. Conditions to Effectiveness. This Amendment shall be effective only upon the
satisfaction of the following conditions:




     (a) the Borrower and the Bank shall have executed and delivered a counterpart of this
Amendment;



-3-









 






     (b) the Borrower shall have consummated the Successful IPO;




     (c) each of the representations and warranties of the Borrower contained in Section 12
shall be true and correct as of the date as of which all of the other conditions contained
in this Section 11 shall have been satisfied; and




     (d) the Bank shall have received such other documents, instruments, certificates,
opinions and approvals as it reasonably may have requested.



     12. Representations and Warranties of the Borrower. As an inducement to the Bank to
enter into this Amendment, the Borrower hereby represents and warrants that on and as of the date
hereof, and taking into account the provisions hereof, the representations and warranties contained
in the Loan Agreement and the other Loan Documents are true and correct in all material respects,
except for representations and warranties that expressly relate to an earlier date, which remain
true and correct as of said earlier date.



     13. Effect of Amendment; Continuing Effectiveness of Loan Agreement and Loan
Documents.




     (a) Neither this Amendment nor any other indulgences that may have been granted to the
Borrower by the Bank shall constitute a course of dealing or otherwise obligate the Bank to
modify, expand or extend the agreements contained herein, to agree to any other amendments
to the Loan Agreement or to grant any consent to, waiver of or indulgence with respect to
any other noncompliance with any provision of the Loan Documents.




     (b) Upon and after the effectiveness of this Amendment, each reference in the Loan
Agreement to “this Agreement”, “hereunder”, “hereof” or words of like import referring to
the Loan Agreement, and each reference in the other Loan Documents to “the Loan Agreement”,
“thereunder”, “thereof” or words of like import referring to the Loan Agreement, shall mean
and be a reference to the Loan Agreement as modified hereby. This Amendment shall
constitute a Loan Document for all purposes of the Loan Agreement and the other Loan
Documents.




     (c) Except to the extent amended or modified hereby, the Loan Agreement, the other Loan
Documents and all terms, conditions and provisions thereof shall continue in full force and
effect in all respects and shall be construed in accordance with the modification of the
Loan Agreement effected hereby.



     14. Release and Waiver. The Borrower hereby stipulates, acknowledges and agrees that
it has no claims or causes of action of any kind whatsoever against the Bank arising out of or
relating in any way to any event, circumstance, action or failure to act with respect to this
Amendment, the Loan Agreement, the other Loan Documents or any matters described or referred to
herein or therein or otherwise related hereto or thereto. The Borrower hereby releases the Bank
from any and all claims, causes of action, demands and liabilities of any kind whatsoever, whether
direct or indirect, fixed or contingent, liquidated or unliquidated, disputed or undisputed, known
or unknown, that the Borrower may now or hereafter have and that arise out of or relate in any way
to any event, circumstance, action or failure to act on or before the date of this Amendment with
respect to this Amendment, the Loan Agreement, the other Loan Documents or any matters described or
referred to herein or therein or otherwise related hereto or thereto. The release by the Borrower
herein, together with the other terms and provisions of this Amendment, are entered into by the
Borrower advisedly and without compulsion, coercion or duress, the Borrower having determined that
this Amendment is in the economic best interests of the Borrower. The Borrower represent that they
are entering into this Amendment freely and with the advice of counsel as to their legal
alternatives.



     15. Further Actions. Each of the parties to this Amendment agrees that at any time
and from time to time upon written request of the other party, it will execute and deliver such
further



-4-









 




documents and do such further acts and things as such other party reasonably may request in
order to effect the intents and purposes of this Amendment.




     16. Counterparts. This Amendment may be executed in multiple counterparts or copies,
each of which shall be deemed an original hereof for all purposes. One or more counterparts or
copies of this Amendment may be executed by one or more of the parties hereto, and some different
counterparts or copies executed by one or more of the other parties. Each counterpart or copy
hereof executed by any party hereto shall be binding upon the party executing same even though
other parties may execute one or more different counterparts or copies, and all counterparts or
copies hereof so executed shall constitute but one and the same agreement. Each party hereto, by
execution of one or more counterparts or copies hereof, expressly authorizes and directs any other
party hereto to detach the signature pages and any corresponding acknowledgment, attestation,
witness or similar pages relating thereto from any such counterpart or copy hereof executed by the
authorizing party and affix same to one or more other identical counterparts or copies hereof so
that upon execution of multiple counterparts or copies hereof by all parties hereto, there shall be
one or more counterparts or copies hereof to which is(are) attached signature pages containing
signatures of all parties hereto and any corresponding acknowledgment, attestation, witness or
similar pages relating thereto.



     17. Miscellaneous.




     (a) This Amendment shall be governed by, construed and enforced in accordance with the
laws of the State of Tennessee, without reference to the conflicts or choice of law
principles thereof.




     (b) The headings in this Amendment and the usage herein of defined terms are for
convenience of reference only, and shall not be construed as amplifying, limiting or
otherwise affecting the substantive provisions hereof.




     (c) All references herein to the preamble, the recitals or sections, paragraphs,
subparagraphs, annexes or exhibits are to the preamble, recitals, sections, paragraphs,
subparagraphs, annexes and exhibits of or to this Amendment unless otherwise specified. The
words “hereof”, “herein” and “hereunder” and words of similar import, when used in this
Amendment, refer to this Amendment as a whole and not to any particular provision of this
Amendment.




     (d) Any reference herein to any instrument, document or agreement, by whatever
terminology used, shall be deemed to include any and all amendments, modifications,
supplements, extensions, renewals, substitutions and/or replacements thereof as the context
may require.




     (e) When used herein, (1) the singular shall include the plural, and vice versa, and
the use of the masculine, feminine or neuter gender shall include all other genders, as
appropriate, (2) “include”, “includes” and “including” shall be deemed to be followed by
“without limitation” regardless of whether such words or words of like import in fact follow
same, and (3) unless the context clearly indicates otherwise, the disjunctive “or” shall
include the conjunctive “and”.



     IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be duly executed and
delivered as of the date first written above.



[Remainder of Page Intentionally Left Blank;

Signature Pages Follow]




-5-









 








[Signature Page to Second Amendment to Second Amended and Restated Loan Agreement

(Cumberland Pharmaceuticals, Inc.) dated July 18, 2007]




	 	 	 	 	 
	 	BORROWER:





CUMBERLAND PHARMACEUTICALS, INC.

 	 
	 	By:  	/s/ A.J. Kazimi
 	 
	 	 	Name:  	A.J. Kazimi 	 
	 	 	Title:  	Chief Executive Officer 	 
	 



ACKNOWLEDGED:



CUMBERLAND EMERGING TECHNOLOGIES, INC.




	 	 	 	 	 
	 	 	 
	By:  	/s/ David L. Lowrance
 	 	 
	 	Name:  	David L. Lowrance 	 	 
	 	Title:  	CFO 	 	 



-6-









 






	 	 	 	 	 



[Signature Page to Second Amendment to Second Amended and Restated Loan Agreement

(Cumberland Pharmaceuticals, Inc.) dated July 18, 2007]




	 	 	 	 	 
	 	BANK:





BANK OF AMERICA, N.A.

 	 
	 	By:  	/s/ Suzanne B. Smith
 	 
	 	 	Name:  	Suzanne B. Smith 	 
	 	 	Title:  	Senior Vice President 	 
	 




-7-